DelistingNov 2, 2026, 04:32 PM
POMDOCTOR Receives Nasdaq Delisting Warnings for MVLS and MVPHS Deficiencies
AI Summary
POMDOCTOR LIMITED announced it received two letters from Nasdaq indicating deficiencies in continued listing requirements. The company no longer meets the minimum market value of listed securities (MVLS) of $50 million and the minimum market value of publicly held shares (MVPHS) of $15 million. POMDOCTOR has 180 days, until April 26, 2027, to regain compliance for both requirements. Failure to do so could lead to delisting, though the company may appeal the decision. The company is evaluating options to meet these requirements.
Key Highlights
- POMDOCTOR received two Nasdaq notifications for failing to meet continued listing requirements.
- Company no longer meets MVLS requirement of $50 million, with a compliance period until April 26, 2027.
- Company also fails MVPHS requirement of $15 million, with a compliance period until April 26, 2027.
- Failure to regain compliance may result in securities being subject to delisting.
- Company intends to monitor MVLS and MVPHS and evaluate options to regain compliance.
Price Impact
More from POM